Short answer
Upstream Bio, Inc. (UPB) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results and business highlights announced for quarter ended June 30, 2026.
Upstream Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results and business highlights announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial and operational details
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 severe asthma and CRSwNP trials remain targeted for Q1 2027, preserving key clinical-development catalysts
- COPD Phase 2 enrollment completed with 481 participants; data expected in the second half of 2027
- Cash, cash equivalents and short-term investments totaled $261.3 million, expected to fund planned operations through 2027
- Second-quarter net loss $39.7 million versus $40.0 million; R&D expense declined to $36.1 million from $37.9 million
- CRSwNP responder analyses showed approximately 80% improved nasal polyp scores, with 72% improving congestion and 83% total symptoms
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Upstream Bio, Inc. 8-K filings
Get the next UPB 8-K as it lands
Follow UPB for push alerts, or ask the research agent what this filing means.